Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. Bröckelmann PJ, et al. Among authors: engert a. J Clin Oncol. 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. J Clin Oncol. 2023. PMID: 36508302 Clinical Trial.
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A. Bröckelmann PJ, et al. Among authors: engert a. J Clin Oncol. 2021 Jan 10;39(2):107-115. doi: 10.1200/JCO.20.00947. Epub 2020 Oct 15. J Clin Oncol. 2021. PMID: 33058716
Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.
Eichenauer DA, Goergen H, Plütschow A, Wongso D, Behringer K, Kreissl S, Thielen I, Halbsguth T, Bröckelmann PJ, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A. Eichenauer DA, et al. Among authors: engert a. Leukemia. 2016 Jun;30(6):1425-7. doi: 10.1038/leu.2015.321. Epub 2015 Nov 20. Leukemia. 2016. PMID: 26585412 Clinical Trial. No abstract available.
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.
Eichenauer DA, Kreissl S, Bühnen I, Baues C, Kobe C, van Heek L, Goergen H, Fuchs M, Hartmann S, von Tresckow B, Engert A, Borchmann P. Eichenauer DA, et al. Among authors: engert a. Ann Oncol. 2021 Jun;32(6):807-810. doi: 10.1016/j.annonc.2021.02.018. Epub 2021 Mar 3. Ann Oncol. 2021. PMID: 33667668 Free article. No abstract available.
New drugs in the treatment of Hodgkin's disease.
Borchmann P, Schnell R, Diehl V, Engert A. Borchmann P, et al. Among authors: engert a. Ann Oncol. 1998;9 Suppl 5:S103-8. doi: 10.1093/annonc/9.suppl_5.s103. Ann Oncol. 1998. PMID: 9926247 Review.
595 results